Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Atreca  (Stock symbol: BCEL )

500 Saginaw Drive, First Floor
Redwood City, CA 94063
USA
650.595.2595
Website Company Summary Management Team
Management

CEO: John A Orwin (4/19/2018)
General Management: Jonathan Benjamin (3/31/2017) ; Wayne Volkmuth (2012)
Finance: Jonathan Woo (2011) ; Cheryl Vincent Garcia (4/30/2019) ; Herb C Cross (3/4/2019)
Technology: Daniel Emerling (2011) ; Guy Cavet (7/31/2014) ; Norman Michael Greenberg ; Stephen Gould (06/17/2022) ; Yann Chong Tan (10/31/2012)
Sales/Marketing: Tito A Serafini
Business Development: Paulette A Dillon
Board

Outside board: (May no longer be on the board) Brian G Atwood (Versant Ventures Managing Director) Franklin M Berger (J.P. Morgan Securities Managing Director) William H Robinson (Atreca co-Founder) Lawrence Steinman (Stanford University School of Medicine Professor) David L Lacey (Amgen)
Company

Business description: Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies.
Partners include: Johnson & Johnson Innovation
Capital

Rounds: 4
Recent Fundings: Sep 2018   Aug 2017
Capital raised: 222.8M
Last Round: 125.0M
Ownership: Public   Ipo Filing
Stock Symbol: BCEL
Private equity: Cormorant Asset Management
Other investors: BillAndMelinda Gates Foundation

Last Tweets


 

Last Mentions


Overview
Record updated: Jun 2022
Sector: Biotech
Year Founded: 2010
Headcount: 101-150 as of Jun 2022
Rounds: 4
Recent Fundings: Sep 2018   Aug 2017
Capital Raised: 222.8M
Last Round: 125.0M
Ownership: Public   Ipo Filing
Stock Symbol: BCEL